News and Press Releases
New Phesi proof of concept demonstrates potential of AI-powered digital twins to replace external control arms in clinical trials
Study published in Bone Marrow Transplantation uses real-world clinical data to create virtual digital twin cohorts instead of placebo and standard-of-care comparator arms 20 June 2024 -- Massachusetts, US --...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2024
China’s Innovent holds potential to change pancreatic cancer treatment landscape with bispecific antibody IBI389, says GlobalData
14 June 2024 - China-based Innovent Biologics recently presented phase 1 study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer at the 2024...
Category: Biotechnology, Pharmaceutical
Posted: June 14, 2024
Tapinarof may mark Dermavant’s first atopic dermatitis approval, says GlobalData
Dermavant's VTAMA (tapinarof), a nonsteroidal, topical AhR-modulating agent, achieved positive phase 3 trial results in atopic dermatitis patients aged two and above, leading to Food and Drug Administration (FDA) acceptance...
Category: Drug Discovery, Pharmaceutical
Posted: June 13, 2024
Deep Genomics Expands Executive Leadership and Operations in Latest Strategic Growth Initiative
Company announces executive new hires and marks significant momentum with Cambridge, Massachusetts, US, site opening and Toronto, Canada, office expansion 13 June 2024 -- Massachusetts, US -- Deep Genomics, the...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 13, 2024
480 University Ave, Suite 1300 Toronto, Ontario, Canada, M5G 1V2
IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites
Bold initiative to boost the capacity of research sites enters Beta testing and piloting 12 June 2024 -- North Carolina, US -- IQVIA today announced the launch of One Home...
Category: Clinical Trials, Drug Discovery, Other
Posted: June 12, 2024
CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT
CluePoints is a cloud-based software platform for Risk-Based Quality Management (RBQM) and data quality oversight in clinical trials, designed to enable safer and more efficient processes and improving data integrity...
Category: Biotechnology, Clinical Trials
Posted: June 12, 2024
SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases
12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage
11 June 2024 -- Lund, Sweden -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected Exothera, a leading...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 11, 2024
CRISM Therapeutics Corp to continue pioneering R&D at PHTA following listing on the London Stock Exchange
11 June 2024 -- Birmingham, UK -- CRISM Therapeutics Corporation a UK-based pharmaceutical company focused on improving the clinical performance of cancer treatments for solid tumours, has raised £2.0m to...
Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: June 11, 2024
Kingston Chambers, PO Box 173, Road Town Tortola, British Virgin Islands
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
TECVAYLI▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing Separate analyses from the MajesTEC-1 and OPTec...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brain
The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
DARZALEX (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma
88% of transplant-eligible patients achieved a complete response or better, and 47% of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous formulation-based regimens in the phase 3...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Lykos Therapeutics Appoints Finance Veteran Scott Giacobello to the Board of Directors
30 May 2024 -- California, US -- Lykos Therapeutics, a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective immediately. A...
Category: Biotechnology, Clinical Trials, Other
Posted: May 30, 2024
Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
SOD1-ALS is a devastating, uniformly fatal and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe QALSODY is Biogen’s third rare disease therapy to be...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 30, 2024
